Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atopic dermatitis.

Peck Y Ong1, Mark Boguniewicz

  • 1Division of Clinical Immunology-Allergy, Childrens Hospital Los Angeles, University of Southern California Keck School of Medicine, 4650, Sunset Boulevard, MS# 75, Los Angeles, CA 90027, USA. pyong@chla.usc.edu

Primary Care
|January 22, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year.

The British journal of dermatology·2026
Same author

Refining pediatric eczema severity assessment with Three-Item Severity score and Patient Oriented Eczema Measure.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

Journal of asthma and allergy·2026
Same author

Atopic dermatitis Yardstick: A new era of topical and systemic treatments.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Pediatric dermatology·2026
Same author

The Next Frontier Is Here: Targeted Systemic Therapies for Allergic and Immunologic Diseases.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Primary Care at the Center of America's Mental Health Landscape.

Primary care·2026
Same journal

We Care, and We Will Listen.

Primary care·2026
Same journal

Addressing Sexual Health in Primary Care.

Primary care·2026
Same journal

Diagnosis and Management of Eating Disorders in Adolescents and Young Adults.

Primary care·2026
Same journal

Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment.

Primary care·2026
Same journal

Nonpharmacologic Management of Insomnia Disorder in Primary Care.

Primary care·2026
See all related articles

Atopic dermatitis is a chronic inflammatory skin disease causing significant morbidity. Comprehensive treatment involves barrier repair, trigger elimination, and anti-inflammatory/antimicrobial use for managing this challenging condition.

Area of Science:

  • Dermatology
  • Immunology
  • Allergy

Background:

  • Atopic dermatitis is a complex, chronic inflammatory skin condition.
  • Moderate to severe cases lead to significant morbidity, impacting daily life.
  • Treatment presents challenges for affected individuals.

Purpose of the Study:

  • To outline a comprehensive treatment approach for atopic dermatitis.
  • To highlight key components of managing this skin disease.
  • To discuss alternative therapies for severe, refractory cases.

Main Methods:

  • Focus on restoring skin barrier function.
  • Emphasis on identifying and eliminating allergic and nonallergic triggers.
  • Proper application of anti-inflammatory and antimicrobial medications.

Related Experiment Videos

Main Results:

  • Comprehensive management improves patient outcomes.
  • Addressing triggers and inflammation is crucial.
  • Alternative treatments offer options for severe disease.

Conclusions:

  • Effective atopic dermatitis management requires a multi-faceted approach.
  • Restoring skin barrier and managing triggers are vital.
  • Wet wraps and immunosuppressants are options for refractory cases.